

Our Pipeline

We challenge ourselves to rethink the way medicines are developed, and are investing now to bring more value to patients in the future.

We strive for constant innovation and we are putting our passion and expertise to work in new areas ophthalmology, gastroenterology, and hematology.

SB8

Biosimilar candidate

Molecule	Bevacizumab
Reference Biologic	Avastin® ⁱ
Therapeutic Area	Oncology



[Learn more about the clinical trial](#)

SB11

Biosimilar candidate

Molecule	Ranibizumab
Reference Biologic	Lucentis® ⁱⁱ
Therapeutic Area	Ophthalmology



[Learn more about the clinical trial](#)

SB12

Biosimilar candidate

Molecule	Eculizumab
Reference Biologic	Soliris® ⁱⁱⁱ
Therapeutic Area	Hematology



[Learn more about the clinical trial](#)

SB15

Biosimilar candidate

Molecule	Aflibercept
Reference Biologic	Eylea® ^{iv}
Therapeutic Area	Ophthalmology



SB26

Novel biologic

Molecule	Ulinastatin-Fc Fusion Protein
Therapeutic Area	Gastroenterology



[Learn more about the clinical trial](#)

★ Pipeline la:

- i Avastin® is a registered trademark of Genentech
- ii Lucentis® is a registered trademark of Genentech
- iii Soliris® is a registered trademark of Alexion
- iv Eylea® is a registered trademark of Regeneron

Our Products

Our Partners

[PRIVACY POLICY \(ONLINE\)](#)

[PRIVACY NOTICE](#)

[TERMS OF USE](#)

[COMMUNITY GUIDELINES](#)

[BUSINESS ETHICS](#)

[COMPLIANCE](#)

[S](#)

Copyright © 2019 Samsung Bioepis. All